MedTrace Logo

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

NCT01582672 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 462

Last updated 2018-06-14

No results posted yet for this study

Summary

This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003 in combination with standard treatment versus subjects treated with standard treatment alone.

Conditions

Interventions

DRUG

Standard Treatment

Standard treatment for Renal Cell Carcinoma

BIOLOGICAL

AGS-003

Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.

Sponsors & Collaborators

  • Argos Therapeutics

    lead INDUSTRY

Principal Investigators

  • Robert Figlin, MD, FACP · Cedars-Sinai Medical Center

  • Christopher G Wood, MD, FACP · M.D. Anderson Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States
  • Canada
  • Czechia
  • Hungary
  • Israel
  • Italy
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01582672 on ClinicalTrials.gov